| Title： | Expert Consensus on HIV Drug Resistance Testing and Clinical Management |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinical workers, especially those specialized in infectious diseases or HIV infection. |
| Evidence classification method： | Recommendation Strengths: A: Strongly recommended B: Moderately recommended C: Optional Corresponding Levels of Evidence: I: At least one randomized controlled trial or a meta-analysis II: At least one non-randomized study or observational cohort study III: Expert opinion |
| Development unit： | First Affiliated Hospital, Zhejiang University School of Medicine |
| Registration time: | 2024-10-30 |
| Registration number： | PREPARE-2024CN971 |
| Purpose of the guideline: | With the widespread of antiretroviral therapy, the issue of HIV drug resistance has gradually attracted people's attention. The timing and method of HIV drug resistance testing, as well as how to avoid the emergence and spread of HIV drug resistance in clinical practice, are urgent issues that need to be addressed. This consensus will comprehensively review the relevant literature on HIV drug resistance testing and clinical management, and summarize the relevant content of HIV drug resistance testing based on expert recommendations, and provide corresponding treatment suggestions. |
Latest registration
